Home Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease
 

Keywords :   


Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease

2014-11-05 05:46:07| drugdiscoveryonline Home Page

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, recently announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease

Tags: with study eye phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.06Atlantic Tropical Weather Outlook
01.06Eastern North Pacific Tropical Weather Outlook
01.06Eastern North Pacific Tropical Weather Outlook
01.06Atlantic Tropical Weather Outlook
31.05Vytelle expands to Melbourne, Australia with its 21st global bovine IVF lab
31.05USDA celebrates 100 years of agriculture innovation
31.05Bob Pasquale elected president of ARC
31.05Eastern North Pacific Tropical Weather Outlook
More »